EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders: Innovations and Limitations Compared to Traditional Strategies

Raffaele Ricci, Gaia Colasante

Developmental Neuroscience · 2021 · 43 (3-4) · 253-261

DOI: 10.1159/000515845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Developmental Neuroscience, online erschienen am 03.05.2021. Verfasst von Raffaele Ricci und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Neurogenesis Unit, Division of Neuroscience, Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neurodevelopmental Disorders. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain development is a complex process that requires a series of precise and coordinated events to take place. When alterations in some of those events occur, neurodevelopmental disorders (NDDs) may appear, with their characteristic symptoms, including cognitive, social motor deficits, and epilepsy. While pharmacologic treatments have been the only therapeutic options for many years, more recently the research is turning to the direct removal of the underlying genetic cause of each specific NDD. This is possible thanks to the increased knowledge of genetic basis of those diseases and the enormous advances in genome-editing tools. Together with clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based strategies, there is a great development also of nuclease defective Cas9 (dCas9) tools that, with an extreme flexibility, allow the recruitment of specific protein functions to the desired genomic sites. In this work, we review dCas9-based tools and discuss all the published applications in the setting of therapeutic approaches for NDDs at the preclinical level. In particular, dCas9-based therapeutic strategies for Dravet syndrome, transcallosal dysconnectivity caused by mutations in C11orf46 gene, and Fragile X syndrome are presented and discussed. A direct comparison with other possible therapeutic strategies, such as classic gene replacement or CRISPR/Cas9-based strategies, is provided. We also highlight not only those aspects that constitute a clear advantage compared to previous strategies but also the main technical hurdles related to their applications that need to be overcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeurodevelopmental DisordersGene EditingGenetic TherapyHumansMutation

Stichwörter der Autor:innen

CRISPR/dCas9Gene therapyNeurodevelopmental disorders

Autor:innen und Institutionen

  • Stem Cell and Neurogenesis Unit, Division of Neuroscience, Ospedale San Raffaele, Milan, Italy.
  • Translational and Molecular Medicine PhD Program, DIMET, University of Milan-Bicocca, Milan, Italy.

Zitieren

APA

Ricci, R., & Colasante, G. (2021). CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders: Innovations and Limitations Compared to Traditional Strategies. Developmental Neuroscience, 43(3-4), 253-261. https://doi.org/10.1159/000515845

Vancouver

Ricci R, Colasante G. CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders: Innovations and Limitations Compared to Traditional Strategies. Developmental Neuroscience. 2021;43(3-4):253-261. doi:10.1159/000515845

BibTeX
@article{Ricci2021,
  author = {Ricci, Raffaele and Colasante, Gaia},
  title = {CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders: Innovations and Limitations Compared to Traditional Strategies},
  journal = {Developmental Neuroscience},
  year = {2021},
  volume = {43},
  number = {3-4},
  pages = {253--261},
  doi = {10.1159/000515845}
}
Kostenlos starten →